SLC25A1 and glioblastoma: Here, we selected lung and glioblastoma cell lines without described mutation in IDH to investigate if treatment with a more specific 3rd generation small molecule SLC25A1 inhibitor CTPI2 [17] would induce D-2-HG accumulation and mimic the HR-ness phenotype of IDH1/2 deficient cells.